Boston Scientific to Acquire Claret Medical
July 20, 2018—Boston Scientific Corporation announced it has signed an agreement to acquire Claret Medical, Inc., a privately held company that has developed and commercialized the Sentinel cerebral embolic protection system. Claret Medical is based in Santa Rosa, California, and has approximately 120 employees.
The Sentinel system received CE Mark approval in 2014 and FDA clearance in 2017 and is designed to protect patients against the risk of stroke during transcatheter aortic valve replacement procedures.
According to Boston Scientific, the transaction price includes $220 million in upfront cash and a potential reimbursement-based milestone payment of up to $50 million. The acquisition is projected to close during the third quarter of 2018, subject to customary closing conditions.